GANTRISIN Drug Patent Profile
✉ Email this page to a colleague
When do Gantrisin patents expire, and when can generic versions of Gantrisin launch?
Gantrisin is a drug marketed by Roche and is included in five NDAs.
The generic ingredient in GANTRISIN is sulfisoxazole. There are three drug master file entries for this compound. Additional details are available on the sulfisoxazole profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for GANTRISIN?
- What are the global sales for GANTRISIN?
- What is Average Wholesale Price for GANTRISIN?
Summary for GANTRISIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 5 |
| Raw Ingredient (Bulk) Api Vendors: | 125 |
| Patent Applications: | 4,197 |
| DailyMed Link: | GANTRISIN at DailyMed |
US Patents and Regulatory Information for GANTRISIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Roche | GANTRISIN | sulfisoxazole diolamine | INJECTABLE;INJECTION | 006917-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Roche | GANTRISIN | sulfisoxazole acetyl | SYRUP;ORAL | 009182-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Roche | GANTRISIN | sulfisoxazole diolamine | OINTMENT;OPHTHALMIC | 008414-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
